OGT and QIAGEN Announce Partnership that Unlocks a Complete Sample to Report Workflow for SureSeq NGS Panels

Oxford, UK – 18 September 2025

* The new co-marketing and distribution partnership enables SureSeq™ NGS panel customers to purchase QIAGEN’s tertiary analysis software QIAGEN Clinical Insight (QCI®) Interpret as part of a complete SureSeq NGS workflow solution, unlocking comprehensive analysis from sample to report
 
* QIAGEN Digital Insights bioinformatics bring over 25 years of expertise in expert-curated content, AI-powered proprietary algorithms and user-friendly tools to simplify NGS data analysis
 
* OGT, a Sysmex Group company, brings decades of unique clinical genomics experience to develop leading hybridization-based NGS technology delivering the insights clinical research laboratories need, every time
 
The partnership between OGT, a global leader in genomic research and diagnostic solutions, and QIAGEN Digital Insights (QDI), a leading provider of genomic interpretation and analysis tools, expands OGT’s bioinformatics capabilities by integrating QIAGEN’s advanced tertiary analysis solution, QCI Interpret, with its SureSeq™ NGS panels. Purpose-built for variant interpretation and clinical reporting, QCI Interpret delivers AI-powered, expert-curated classifications along with oncologist-reviewed summaries and transparent evidence links. Through this collaboration, SureSeq™ NGS panel users gain access to streamlined, high-confidence genomic insights and efficient, scalable reporting from sample to result.
 
QDI has built the world’s largest expert-curated knowledge base of genomic and bioinformatic content, serving as the foundation of QCI Interpret. By combining the clinical precision of expert (MD/PhD) curation with the speed and scalability of AI-powered automation, QCI Interpret enables labs to deliver high-confidence variant interpretation and reporting.  QCI Interpret empowers SureSeq customers with transparent variant classifications, oncologist-reviewed summaries, and on-demand interpretations—streamlining the path from sequencing to final report.
 
OGT’s suite of SureSeq NGS products has been developed with superior hybridisation-based detection capabilities to ensure clinical research labs effortlessly achieve comprehensive genomic profiling of their samples and minimise the risk of missing variants. Combined with the unmatched accuracy and consistency of QIAGEN’s proprietary software, labs gain access to an end-to-end workflow for faster, better-informed and more confident insights.
 
Gareth Thomson, Executive Vice President of Commercial Operations at OGT, commented “We are delighted to be partnering with QIAGEN Digital Insights to allow OGT’s customers to package their SureSeq NGS panels with QIAGEN Digital Insights tertiary analysis software creating an end-to-end NGS workflow with access to the world’s largest knowledge base increasing customers confidence in variant classification. This partnership is an important demonstration of OGT’s commitment to providing the most relevant and impactful oncology insights”.
 
“We are pleased to partner with OGT to deliver an even greater impact to labs worldwide,” said Nitin Sood, Senior Vice President and head of Life Sciences at QIAGEN. “This collaboration reinforces QIAGEN Digital Insights’ global leadership in variant interpretation to deliver scalable, collaborative and cutting-edge solutions for precision medicine. As labs face mounting challenges with the complexity and volume of NGS testing, QDI is uniquely positioned to support SureSeq workflows with transparent variant classifications, oncologist-reviewed insights and flexible reporting. This helps customers to scale confidently, reduce turnaround times, and improve outcomes for patients.”
 
As part of Sysmex, the world’s largest haematology diagnostics provider, OGT’s partnership with QIAGEN further progresses the shared mission of improved diagnostics and testing, bringing expertise together to support labs and researchers to shape the advancement of healthcare.
 
More information on the OGT’s SureSeq NGS products can be found here:  https://www.ogt.com/products/technology/sureseq-ngs/ 
 
More information on the QIAGEN Digital Insights can be found here:  https://digitalinsights.qiagen.com/ 
 
About OGT
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 30 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. With OGT’s precision medicine partnerships, we strive to accelerate clinical trial assay and companion diagnostic development programmes to help our partners make the right decisions every time. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
 
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell®: Some products may not be available in your region.
For more information on the Company, please visit our website at www.ogt.com
 
About Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. The company employs more than 10,000 employees worldwide. Sysmex Corporation is listed in the Prime Market on the Tokyo Stock Exchange.
 
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/
 
About QIAGEN Digital Insights
QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, is the leading provider of genomic and clinical knowledge, analysis and interpretation tools, and services for scientists and clinicians. QDI has over 90,000 users worldwide, over 100,000 citations in scientific papers, more than 5 million profiled patient cases, and over 40 billion scientific data points. The portfolio includes expertly curated genomic and clinical knowledge solutions as well as bioinformatics software and services for efficient data management, sharing, and actionable insights.
 
Learn more at https://digitalinsights.qiagen.com/